Liver Organoid Culture: Hepatocyte Differentiation and Functional Maturation

1. Introduction to Liver Organoid Technology

The liver is the largest internal organ in the human body and performs over 500 essential functions, including protein synthesis, detoxification, drug metabolism, bile production, and glucose homeostasis. Its cellular architecture is remarkably complex, comprising hepatocytes (which constitute approximately 70% of the liver cell mass), cholangiocytes (biliary epithelial cells lining the bile ducts), Kupffer cells (resident macrophages), hepatic stellate cells, sinusoidal endothelial cells, and various immune cell populations. This cellular diversity, combined with the liver's unique metabolic zonation and regenerative capacity, has made it challenging to model in vitro using conventional cell culture systems [1,2].

Liver organoid technology has emerged as a transformative platform for studying liver development, modeling metabolic and genetic liver diseases, studying viral infections (including hepatitis B and C), evaluating drug-induced liver injury (DILI), and investigating hepatocellular carcinoma and cholangiocarcinoma. The first adult liver organoid protocols were established by Huch and colleagues in 2013, who demonstrated that bipotent adult liver progenitors (hepatoblasts) residing in the bile ducts could be expanded indefinitely in 3D culture while retaining the capacity to differentiate into both functional hepatocytes and cholangiocytes [3]. This breakthrough was followed by the establishment of human liver organoid cultures in 2015, which demonstrated long-term genomic stability and the ability to model genetic liver diseases such as α1-antitrypsin deficiency and Alagille syndrome [4].

Liver organoids can be generated from two primary sources: adult stem cells (ductal cells or hepatoblasts) and pluripotent stem cells (PSCs) through directed differentiation. Adult stem cell-derived liver organoids offer the advantages of direct derivation from mature tissue, rapid establishment, and inherent recapitulation of adult liver architecture, while PSC-derived liver organoids enable the modeling of developmental processes, genetic diseases, and the generation of patient-specific models from any individual [2,5]. This article provides comprehensive protocols for liver organoid expansion, hepatocyte differentiation, cholangiocyte differentiation, and functional validation, with detailed technical parameters and quality control measures.

2. Fundamental Principles of Liver Organoid Culture

The culture of liver organoids is based on the recapitulation of the hepatic stem cell niche, which provides the signals necessary for the self-renewal and bipotent differentiation capacity of liver progenitor cells. In the adult liver, bipotent progenitors are located in the canals of Hering and small bile ducts, where they can respond to liver injury by proliferating and differentiating into both hepatocytes and cholangiocytes. The niche signals that maintain these progenitors include Wnt signaling (via R-spondin 1 and Wnt3a), EGF signaling, FGF10 signaling, and HGF signaling, while BMP signaling is inhibited by Noggin to prevent premature differentiation [3,4].

Additional factors that promote the expansion and maintenance of bipotent liver progenitors include:

• Nicotinamide (10 mM): A form of vitamin B3 that enhances organoid formation and long-term stability by suppressing sirtuin activity and promoting cellular metabolism. Nicotinamide is essential for both mouse and human liver organoid culture and significantly extends the lifespan of the cultures [4,6].
• Forskolin (10 µM): An activator of adenylate cyclase that increases intracellular cAMP levels. Forskolin promotes biliary differentiation and enhances organoid formation, particularly during the initiation phase [4,6].
• BMP7 (25 ng/mL): A bone morphogenetic protein that promotes hepatocyte lineage development and enhances the differentiation efficiency of hepatoblasts toward mature hepatocytes [4,7].

Hepatocyte differentiation is achieved by withdrawing pro-proliferative signals (R-spondin 1, HGF, nicotinamide) and adding differentiation cues including Notch inhibitors (DAPT), TGF-β inhibitors (A83-01), and glucocorticoids (dexamethasone). The withdrawal of Wnt signaling (by removing R-spondin 1) is particularly critical, as Wnt signaling maintains the progenitor state and must be suppressed to allow hepatocyte maturation [3,4,6].

Cholangiocyte differentiation, in contrast, requires the activation of TGF-β signaling (via activin A) and the addition of retinoic acid, which promotes the biliary fate. FGF10 is also maintained during cholangiocyte differentiation to support ductal morphogenesis [3,8].

3. Tissue Procurement and Cell Isolation Protocols

3.1 Human Liver Tissue Processing and Ductal Cell Isolation

The successful establishment of human liver organoids depends critically on the quality of the starting tissue and the efficiency of progenitor cell isolation. The following protocol is optimized for fresh liver tissue obtained from surgical resections, biopsies, or donor organs.

Materials Required:

• Fresh human liver tissue (surgical resection, biopsy, or research tissue from organ procurement)
• Ice-cold phosphate-buffered saline (PBS) with antibiotics
• Advanced DMEM/F12 medium
• Collagenase (Type I or II, 0.5–1 mg/mL) and dispase (0.5 mg/mL)
• 15 mL and 50 mL conical tubes
• 100 µm and 40 µm cell strainers
• Dissection microscope
• Refrigerated centrifuge
• Scalpels, scissors, and forceps

Detailed Procedure:

1. Obtain fresh liver tissue and transport immediately in ice-cold PBS supplemented with 100 µg/mL Primocin and 100 U/mL Penicillin/Streptomycin. Process within 6 hours of collection for optimal viability.
2. Transfer the tissue to a 10 cm petri dish containing ice-cold PBS. Wash the tissue extensively to remove blood and bile. Using sterile scissors and forceps, dissect the bile ducts from the liver parenchyma. The bile ducts appear as small, white, tubular structures branching through the liver tissue. Under a dissection microscope, carefully isolate the small intrahepatic bile ducts (ducts <1 mm in diameter) using fine forceps and micro-scissors. Avoid large bile ducts (>2 mm), which contain more differentiated cholangiocytes and fewer progenitor cells [3,4].
3. Transfer the isolated bile duct fragments to a 15 mL tube containing digestion buffer: DMEM/F12 + collagenase (0.5 mg/mL) + dispase (0.5 mg/mL) + DNase I (0.1 mg/mL). Incubate at 37°C for 30–45 minutes with gentle agitation (100 rpm on an orbital shaker). Monitor the digestion under a microscope; the ducts should begin to dissociate into small epithelial clusters and single cells. Stop the digestion when the majority of the tissue has dissociated into clusters of 5–50 cells.
4. Stop the enzymatic reaction by adding an equal volume of cold Advanced DMEM/F12 + 10% FBS. Pass the suspension through a 100 µm strainer followed by a 40 µm strainer to remove undigested fragments and large clumps.
5. Centrifuge at 200–300 × g for 5 minutes at 4°C. Carefully aspirate the supernatant and resuspend the pellet in 5 mL of cold Advanced DMEM/F12. Centrifuge again at 200 × g for 5 minutes.
6. After the final wash, resuspend the cell pellet in an appropriate volume of cold Matrigel for plating. The cell density should be approximately 5,000–20,000 cells per 30 µL Matrigel droplet [4,6].

3.2 Murine Liver Organoid Isolation

1. Euthanize the mouse using an approved method and expose the abdominal cavity. The liver should be perfused with PBS through the portal vein to remove blood, which can interfere with organoid formation. Insert a 25-gauge needle into the portal vein and perfuse gently with 10–20 mL of ice-cold PBS until the liver turns pale.
2. Dissect the liver and place it in a petri dish with ice-cold PBS. Under a dissection microscope, identify and isolate the bile ducts from the liver parenchyma. The murine bile duct system is more delicate than the human system, so extreme care is required to avoid damaging the ducts during isolation.
3. Mince the isolated ducts into small fragments and digest with collagenase/dispase as described for human tissue. The digestion time for mouse tissue is typically shorter (20–30 minutes) due to the smaller tissue size.
4. Filter, wash, and resuspend the cells in Matrigel for plating [3,4].

3.3 Hepatocyte-Derived Liver Organoids

In addition to ductal cell-derived organoids, liver organoids can also be established from primary hepatocytes. This approach is particularly useful for studying hepatocyte-specific biology and for generating organoids from hepatocyte-rich tissue (such as normal liver parenchyma). The protocol involves:

1. Perfuse the liver with collagenase (1 mg/mL) via the portal vein at 37°C for 10–15 minutes to digest the liver parenchyma.
2. Gently disaggregate the liver capsule and release the hepatocytes into ice-cold DMEM/F12 + 10% FBS.
3. Filter the cell suspension through a 100 µm strainer and centrifuge at 50 × g for 5 minutes. Hepatocytes are large cells and have a low sedimentation velocity; therefore, a low centrifugation speed is used to pellet hepatocytes while leaving smaller non-parenchymal cells in the supernatant.
4. Wash the hepatocyte pellet twice with cold PBS and resuspend in Matrigel for plating. Hepatocyte-derived organoids typically require higher concentrations of HGF (50 ng/mL) and FGF10 (100 ng/mL) for successful organoid formation [4,7].

4. Culture Media Formulation and Preparation

4.1 Liver Organoid Initiation Medium (Days 0–3)

The initiation medium is designed to promote the survival and initial proliferation of freshly isolated liver progenitor cells during the critical first 3 days of culture. It contains the full complement of niche signals required for stem cell maintenance.

Base: Advanced DMEM/F12 (Gibco, 12634010)

Supplements:

• 2 mM GlutaMAX (Gibco, 35050061)
• 10 mM HEPES (Gibco, 15630080)
• 1× Penicillin/Streptomycin (Gibco, 15140122)
• 1× N21-MAX supplement (R&D Systems, AR009) or 1× B27 supplement + 1× N2 supplement
• 1.25 mM N-acetylcysteine (Sigma-Aldrich, A9165)
• 10 mM Nicotinamide (Sigma-Aldrich, N0636)
• 5 µM A83-01 (Tocris Bioscience, 2939) – TGF-β receptor inhibitor
• 100 ng/mL FGF-10 (recombinant human, PeproTech, 100-26) – promotes hepatoblast proliferation
• 0.5 µg/mL R-Spondin 1 (recombinant human, R&D Systems, 4645-RS) – Wnt pathway amplifier
• 10 nM Gastrin I (human, Sigma-Aldrich, G9145) – stimulates epithelial proliferation
• 25 ng/mL BMP7 (recombinant human, R&D Systems, 354-BP) – promotes hepatocyte lineage development
• 50 ng/mL EGF (recombinant human, PeproTech, AF-100-15)
• 25 ng/mL HGF (recombinant human, PeproTech, 100-39) – hepatocyte growth factor, a potent mitogen for hepatocytes
• 25 ng/mL Noggin (recombinant human, R&D Systems, 6057-NG) – BMP inhibitor
• 100 ng/mL Wnt-3a (recombinant human, R&D Systems, 5036-WN) – canonical Wnt signaling activator
• 10 µM Forskolin (Sigma-Aldrich, F6886) – adenylate cyclase activator
• 10 µM Y-27632 (STEMCELL Technologies, 72302) – ROCK inhibitor, included for the first 48 hours only to prevent anoikis [4,6,7]

4.2 Liver Organoid Expansion Medium (Days 3+)

After the initial 3-day initiation period, the medium is switched to the expansion medium, which maintains the long-term proliferation and self-renewal of bipotent liver progenitors. The expansion medium is similar to the initiation medium but with the removal of Wnt-3a, Noggin, and Y-27632, as these factors are no longer required once the organoids are established.

Base: Advanced DMEM/F12

Supplements:

• 2 mM GlutaMAX
• 10 mM HEPES
• 1× Penicillin/Streptomycin
• 1× N21-MAX supplement (or 1× B27 + 1× N2)
• 1.25 mM N-acetylcysteine
• 10 mM Nicotinamide
• 5 µM A83-01
• 100 ng/mL FGF-10
• 0.5 µg/mL R-Spondin 1
• 10 nM Gastrin I
• 25 ng/mL BMP7
• 50 ng/mL EGF
• 25 ng/mL HGF
• 10 µM Forskolin [4,6,7]

The expansion medium is changed every 2–3 days. Organoids typically require passage every 7–10 days at a 1:3 to 1:6 ratio. Murine liver organoids can be maintained indefinitely (some lines have been cultured for >24 months), while human liver organoids can be maintained for at least 12–18 months with stable karyotypes [4,6].

4.3 Hepatocyte Differentiation Medium

Hepatocyte differentiation is induced by withdrawing pro-proliferative signals and adding differentiation cues that promote the expression of hepatocyte-specific genes and functions. The differentiation protocol typically takes 9–18 days.

Base: Advanced DMEM/F12

Supplements:

• 2 mM GlutaMAX
• 10 mM HEPES
• 1× Penicillin/Streptomycin
• 1× N21-MAX supplement (or 1× B27 + 1× N2)
• 1.25 mM N-acetylcysteine
• 50 ng/mL EGF – reduced compared to expansion medium
• 25 ng/mL BMP7 – maintained to promote hepatocyte fate
• 50 nM A83-01 – maintained to prevent epithelial-mesenchymal transition
• 10 nM DAPT (Tocris Bioscience, 2634) – Notch inhibitor; Notch signaling promotes biliary fate, so its inhibition drives hepatocyte differentiation
• 30 µM Dexamethasone (Sigma-Aldrich, D4902) – glucocorticoid receptor agonist; added during the last 3 days of differentiation to promote terminal maturation [4,6,8]

Critical Notes:

• R-Spondin 1, HGF, and Nicotinamide must be completely withdrawn from the medium, as these factors maintain the progenitor state and prevent hepatocyte differentiation.
• DAPT is essential for hepatocyte differentiation; without Notch inhibition, the organoids will differentiate toward cholangiocytes rather than hepatocytes.
• Dexamethasone drives the final maturation of hepatocytes and promotes the expression of CYP450 enzymes and albumin. It should be added only during the last 3 days of differentiation to avoid premature maturation and reduced cell viability [4,6].

4.4 Cholangiocyte Differentiation Medium

Cholangiocyte differentiation requires the activation of TGF-β signaling and the addition of retinoic acid, which promote the biliary fate. The differentiation is performed in two phases:

• Phase 1 (Days 1–4): Advanced DMEM/F12 + 1× B27 supplement + 50 ng/mL FGF10 + 50 ng/mL Activin A (R&D Systems, 338-AC) + 3 µM Retinoic Acid (Sigma-Aldrich, R2625). Activin A activates TGF-β/activin signaling, which promotes the biliary lineage, while retinoic acid enhances ductal morphogenesis [8,9].
• Phase 2 (Days 5+): Advanced DMEM/F12 + 10 mM Nicotinamide + 17 mM sodium bicarbonate + 0.2 mM 2-phospho-L-ascorbic acid (Sigma-Aldrich, A4544) + 6.3 mM sodium pyruvate + 14 mM glucose + ITS+ premix (BD Biosciences, 354352) + 0.1 µM dexamethasone + 2 mM GlutaMAX + 20 ng/mL EGF. This medium supports the maturation of cholangiocytes and the formation of duct-like structures [8,9].

5. Culture Protocol: From Initiation to Differentiation

5.1 Initiation and Expansion

1. Resuspend the isolated liver cells in cold Matrigel at a density of 5,000–20,000 cells per 30 µL droplet. The optimal density depends on the tissue source and cell viability; for human ductal cells, 10,000 cells per droplet is typically optimal.
2. Plate 30–50 µL droplets in pre-warmed 24-well plates. Ensure that the droplets do not touch the sides of the wells.
3. Polymerize at 37°C for 15 minutes.
4. Add 500 µL of liver organoid initiation medium per well. The Y-27632 in the initiation medium will improve cell survival during the first 48 hours.
5. After 3 days, aspirate the initiation medium and replace with liver organoid expansion medium. Change the medium every 2–3 days thereafter.
6. Monitor organoid formation by brightfield microscopy. Small, spherical organoids should appear within 3–5 days. By day 7–10, the organoids should be well-formed and ready for passage or differentiation.

5.2 Passaging Protocol

1. Remove the medium and add 1 mL of ice-cold Advanced DMEM/F12 per well.
2. Mechanically disrupt the Matrigel dome by scraping with a 1 mL pipette tip. Pipette vigorously 10–20 times to fragment the organoids into small pieces (10–50 cells per fragment).
3. Centrifuge at 200 × g for 5 minutes at 4°C.
4. Resuspend the pellet in cold Matrigel and re-plate at a 1:3 to 1:6 ratio.
5. Add expansion medium and culture as described above [4,6].

5.3 Hepatocyte Differentiation Protocol

1. Expand organoids in expansion medium for 7–10 days until they are well-formed and dense. The organoids should fill approximately 70% of the Matrigel dome before differentiation is initiated.
2. Aspirate the expansion medium and wash the organoids once gently with PBS.
3. Add hepatocyte differentiation medium. The change from expansion medium to differentiation medium should be performed as a complete switch (not a gradual transition) to ensure clear differentiation cues.
4. Change the differentiation medium every other day for 9–18 days. The total differentiation time depends on the desired level of maturation: 9–12 days yields hepatoblast-like cells with intermediate maturity, while 15–18 days yields more mature hepatocyte-like cells with higher levels of albumin secretion and CYP450 activity.
5. For the last 3 days of differentiation (days 16–18 if differentiating for 18 days total), add dexamethasone (30 µM) to the medium to drive final maturation.
6. Assess differentiation success by immunofluorescence staining and functional assays (see Section 6 below) [4,6,8].

6. Quality Control and Functional Validation

6.1 Morphological Assessment

Expansion organoids appear as compact, spherical, or cystic structures with smooth surfaces. Differentiated hepatocyte organoids become larger and more translucent, with polyploid nuclei visible under phase-contrast microscopy. Cholangiocyte organoids form cyst-like structures with a clearly defined central lumen, resembling bile duct morphology. The presence of a central lumen in cholangiocyte organoids indicates proper epithelial polarization and is a positive sign of successful differentiation [4,6,8].

6.2 Immunofluorescence and Flow Cytometry Characterization

Cryosection or whole-mount immunofluorescence staining is used to validate the cellular identity of liver organoids. Key markers include:

Hepatocyte Markers:

• Albumin (the major plasma protein produced by hepatocytes) – Albumin antibody (Abcam ab207327, 1:200)
• HNF4α (hepatocyte nuclear factor 4-alpha, a master regulator of hepatocyte differentiation) – HNF4α antibody (Santa Cruz sc-8987, 1:100)
• MRP2 (multidrug resistance protein 2, an apical transporter involved in bile acid transport) – MRP2 antibody (Abcam ab203397, 1:200)
• CYP3A4 (cytochrome P450 3A4, the major drug-metabolizing enzyme in the liver) – CYP3A4 antibody (Abcam ab124421, 1:100)
• CK18 (cytokeratin 18, an intermediate filament protein expressed in hepatocytes) – CK18 antibody (Abcam ab668, 1:200)
• ASGPR1 (asialoglycoprotein receptor 1, a liver-specific endocytic receptor) – ASGPR1 antibody (R&D Systems, AF1189, 1:100) [4,6,10]

Cholangiocyte Markers:

• CK7 (cytokeratin 7, expressed in cholangiocytes) – CK7 antibody (Abcam ab9021, 1:200)
• CK19 (cytokeratin 19, a biliary marker) – CK19 antibody (Abcam ab133496, 1:200)
• CFTR (cystic fibrosis transmembrane conductance regulator, expressed in cholangiocytes) – CFTR antibody (Abcam ab2784, 1:100)
• Sox9 (SRY-box transcription factor 9, a marker of biliary and progenitor cells) – Sox9 antibody (Cell Signaling 82630, 1:200)
• AQP1 (aquaporin 1, a water channel expressed in cholangiocytes) – AQP1 antibody (Abcam ab9566, 1:200) [8,9,10]

Progenitor Markers:

• Sox9 (also expressed in progenitors)
• Foxl1 (forkhead box L1, a marker of hepatic stellate cells and progenitors)
• EpCAM (epithelial cell adhesion molecule, expressed in bipotent progenitors) – EpCAM antibody (Abcam ab71916, 1:200)
• Lgr5 (in some mouse liver progenitor models) – Lgr5 antibody (Ummuno Diagnostic, 1:500) [4,6]

Flow cytometry can be used to quantify the percentage of hepatocyte-like cells in differentiated organoids. After dissociation to single cells, stain with a hepatocyte surface marker (such as ASGPR1) and analyze by flow cytometry. A successful differentiation protocol should yield 30–50% hepatocyte-like cells (ASGPR1+) after 18 days of differentiation [4,6].

6.3 Functional Assays for Hepatocyte Validation

• Albumin Secretion: The secretion of albumin into the culture medium is the hallmark of hepatocyte function and is typically measured by enzyme-linked immunosorbent assay (ELISA). Collect the culture supernatant every 24–48 hours and measure albumin concentration using a human albumin ELISA kit (e.g., Bethyl Laboratories, E80-129). Differentiated hepatocyte organoids should produce albumin at rates of 1–10 µg/mL per day per 10^6 cells, which is comparable to primary human hepatocytes [4,6,10].
• Urea Synthesis: Hepatocytes convert ammonia to urea via the urea cycle, a function that is not present in other liver cell types. Measure urea in the culture supernatant using a colorimetric urea assay kit (e.g., BioAssay Systems, DIUR-500). Differentiated hepatocyte organoids should synthesize urea in a dose-dependent manner when exposed to ammonium chloride [4,6].
• Cytochrome P450 Activity: The activity of CYP450 enzymes is a critical function of hepatocytes and is essential for drug metabolism studies. Assess CYP1A2, CYP3A4, and CYP2C9 activity using specific luciferin-based substrates (e.g., P450-Glo assays, Promega):
  • CYP3A4 activity: Luciferin-IPA substrate (Promega, V9002)
  • CYP1A2 activity: Luciferin-CEE substrate (Promega, V8772)
  • CYP2C9 activity: Luciferin-H substrate (Promega, V8792)
  Activity should be inducible by prototypical CYP inducers: rifampicin (10 µM) for CYP3A4, 3-methylcholanthrene (2 µM) for CYP1A2, and phenobarbital (1 mM) for CYP2C9. The induction of CYP activity by these compounds demonstrates that the organoids possess functional drug metabolism and regulatory mechanisms [4,6,10].
• Glycogen Storage: Detected by Periodic Acid-Schiff (PAS) staining. Differentiated hepatocyte organoids should accumulate glycogen in the cytoplasm, which stains magenta with PAS. The staining can be quantified by image analysis [4,6].
• Bile Acid Transport: Assess bile acid transport using a fluorescent bile acid analog (such as cholyl-L-lysyl-fluorescein, CLF). Incubate the organoids with CLF (1 µM) for 30 minutes, wash, and visualize by fluorescence microscopy. Functional hepatocytes should take up CLF via the basolateral Na+-taurocholate cotransporting polypeptide (NTCP) and export it via the apical bile salt export pump (BSEP) and MRP2 [4,6,10].
• Lipid Metabolism: Assess lipid synthesis and storage by staining with Oil Red O or BODIPY 493/503. Hepatocytes should accumulate lipid droplets when exposed to fatty acids (e.g., oleic acid, 200 µM). This assay is particularly relevant for modeling non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) [4,6].

7. PSC-Derived Liver Organoids

7.1 Directed Differentiation from iPSCs

PSC-derived liver organoids are generated by directed differentiation through the sequential stages of definitive endoderm, hepatic endoderm, hepatoblast, and mature hepatocyte. This approach is particularly valuable for modeling genetic liver diseases, as patient iPSCs can be used to generate disease-specific liver organoids.

1. iPSCs are maintained in mTeSR1 or StemFlex on Matrigel-coated plates. When the cells reach 70–80% confluency, initiate differentiation.
2. Day 0–3: Definitive Endoderm Induction. Culture the cells in RPMI 1640 + B27 (without insulin) + 100 ng/mL Activin A + 10 ng/mL BMP4 + 3 µM CHIR99021 (Wnt agonist). The cells should transition from a pluripotent morphology to an epithelial morphology with increased cell density.
3. Day 4–6: Hepatic Endoderm Specification. Change to DMEM/F12 + B27 + 10 ng/mL FGF4 + 10 ng/mL BMP2. The cells should begin to express hepatic markers (HNF4α, FOXA2).
4. Day 7–12: Hepatoblast Expansion. Culture in DMEM/F12 + B27 + 10 ng/mL FGF10 + 20 ng/mL HGF + 10 ng/mL Activin A + 20 ng/mL EGF. The cells should express hepatoblast markers (AFP, CK19, HNF4α).
5. Day 13+: Hepatocyte Maturation. Replace the medium with hepatocyte maturation medium: DMEM/F12 + B27 + 20 ng/mL oncostatin M (OSM, R&D Systems, 495-MO) + 1 µM dexamethasone + 10 ng/mL HGF. Oncostatin M is a member of the IL-6 family that promotes hepatocyte maturation and the expression of CYP450 enzymes. Continue maturation for 7–14 days [5,11,12].

8. Troubleshooting Common Issues in Liver Organoid Culture

Issue: Low organoid formation efficiency

Potential Causes and Solutions:

• Tissue is not fresh: Process tissue within 6 hours of collection. Fresh tissue has the highest progenitor cell viability.
• Incorrect bile duct isolation: Ensure that small intrahepatic ducts (<1 mm) are isolated rather than large ducts. Small ducts contain more progenitor cells.
• Digestion is too harsh: Reduce collagenase concentration or digestion time. Over-digestion destroys progenitor cells.
• Y-27632 is omitted: Include Y-27632 (10 µM) during the first 48 hours of initiation.
• Growth factors are inactive: Verify growth factor activity by testing on a known organoid line. Store at −80°C in single-use aliquots [4,6].

Issue: Organoids differentiate spontaneously during expansion

Potential Causes and Solutions:

• R-Spondin 1 concentration is too low: Increase to 1 µg/mL. R-Spondin 1 is essential for maintaining the progenitor state.
• Noggin is omitted or degraded: Verify Noggin activity. Noggin prevents BMP-mediated differentiation.
• A83-01 concentration is insufficient: Increase to 5–10 µM to suppress TGF-β-mediated differentiation.
• Passage at lower density: Overcrowding can promote differentiation due to nutrient depletion and metabolic stress [4,6].

Issue: Poor hepatocyte differentiation

Potential Causes and Solutions:

• Incomplete withdrawal of R-Spondin 1, HGF, or Nicotinamide: Ensure complete removal of these pro-proliferative factors from the differentiation medium.
• DAPT is inactive or omitted: Verify DAPT stock and include at 10 nM. DAPT is essential for Notch inhibition and hepatocyte fate promotion.
• Dexamethasone is not added: Include dexamethasone (30 µM) during the last 3 days of differentiation.
• Differentiation time is too short: Extend differentiation to 15–18 days for mature hepatocytes.
• Organoid density is too high: Differentiate at lower density (1:6 rather than 1:3) to improve nutrient access and differentiation efficiency [4,6,8].

9. Conclusion

Liver organoid culture provides an invaluable platform for studying hepatic biology, modeling liver disease, screening hepatotoxicity and drug efficacy, and exploring regenerative therapies. The ability to expand bipotent liver progenitors indefinitely and direct their differentiation into functional hepatocytes or cholangiocytes enables diverse research applications that were previously impossible with conventional cell culture. GBiowit offers liver organoid culture kits, defined hepatocyte differentiation media, ECM matrices, and specialized services for liver disease modeling, drug metabolism studies, and hepatotoxicity screening.